🇺🇸 MDV3100 in United States

12 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cardiac Failure Congestive — 2 reports (16.67%)
  2. Pulmonary Oedema — 2 reports (16.67%)
  3. Anaemia — 1 report (8.33%)
  4. Anxiety — 1 report (8.33%)
  5. Application Site Haemorrhage — 1 report (8.33%)
  6. Bladder Dilatation — 1 report (8.33%)
  7. Blood Potassium Decreased — 1 report (8.33%)
  8. Blood Pressure Increased — 1 report (8.33%)
  9. Cardiac Ventricular Thrombosis — 1 report (8.33%)
  10. Cardioactive Drug Level Decreased — 1 report (8.33%)

Source database →

MDV3100 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is MDV3100 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for MDV3100 in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.